Bionor’s mission is to enable the immune system to fight HIV infection. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e., the upside potential from partnering or licensing remains with the company.
On December 8, 2017, all shares in Bionor Pharma were acquired by an investor group led by Mr. Birger Sørensen. Mr. Sørensen is the original founder of the Bionor group back in 1985 and served as EVP and Head of Vaccines from 2010 to 2012. Bionor commenced its vaccine development program in 2000.